Recent progress in TGF-β inhibitors for cancer therapy.

Szczegóły
Abstrakt

Tytuł:: Recent progress in TGF-β inhibitors for cancer therapy.
Autorzy:: Huang CY; Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC; Department of Pathology, Kaohsiung Armed Forces General Hospital, Kaohsiung 80284, Taiwan, ROC.
Chung CL; Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC.
Hu TH; Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan, ROC.
Chen JJ; Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei 11221, Taiwan, ROC; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan.
Liu PF; Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 80708, Taiwan ROC.
Chen CL; Department of Biological Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan, ROC; Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 80708, Taiwan ROC; Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 80708, Taiwan ROC. Electronic address: .
Źródło:: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Feb; Vol. 134, pp. 111046. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Paris : Editions Scientifiques Elsevier
Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982-
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Transforming Growth Factor beta/*antagonists & inhibitors
Transforming Growth Factor beta/*metabolism
Animals ; Antibodies, Neutralizing/therapeutic use ; Aptamers, Peptide/therapeutic use ; Cancer Vaccines/therapeutic use ; Carcinogenesis/drug effects ; Clinical Trials as Topic ; Endocytosis/drug effects ; Fibrosis/drug therapy ; Humans ; Membrane Microdomains/metabolism ; Mice ; Oligonucleotides, Antisense/therapeutic use ; Receptors, Transforming Growth Factor beta/antagonists & inhibitors ; Receptors, Transforming Growth Factor beta/metabolism ; Signal Transduction/drug effects
Contributed Indexing:: Keywords: Cancer therapy; Endocytosis; Lipid raft; Small-molecule inhibitor; TGF-β inhibitor
Substance Nomenclature:: 0 (Antibodies, Neutralizing)
0 (Antineoplastic Agents)
0 (Aptamers, Peptide)
0 (Cancer Vaccines)
0 (Oligonucleotides, Antisense)
0 (Receptors, Transforming Growth Factor beta)
0 (Transforming Growth Factor beta)
Entry Date(s):: Date Created: 20201219 Date Completed: 20210701 Latest Revision: 20210701
Update Code:: 20240105
DOI:: 10.1016/j.biopha.2020.111046
PMID:: 33341049
: Czasopismo naukowe

Full Text Finder

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.
(Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)

Informacja